<?xml version="1.0" encoding="UTF-8"?>
<p id="Par59">There are also other registered trials planned to test the efficacy of leflunomid, ecluzimab, and ruxolitinib [
 <xref ref-type="bibr" rid="CR148">148</xref>]. The readers are referred to the review by Lythgoe et al. summarizing all ongoing trials for the management of COVID-19 pandemic [
 <xref ref-type="bibr" rid="CR148">148</xref>].
</p>
